|
Darolutamide |
5-Acetyl-1H-Pyrazole-3-carboxylic acid |
1297537-45-1 |
|
|
2-Chloro-4-(1H-pyazol-3-yl)benzonitrile |
1297537-37-1 |
|
High-affinity AR binding begins with API quality. The complex heterocyclic scaffold of Darolutamide determines its selective AR binding profile and resistance-overcoming activity against mutant ARs. Any impurity in the API could affect receptor binding affinity and therapeutic efficacy. Our analytical release protocol for Darolutamide includes HPLC purity verification (≥98%), chiral purity assessment, identity confirmation via NMR and MS, and residual solvent analysis.
Documentation that supports regulatory submission. Every shipment includes a Certificate of Analysis (COA) with batch-specific HPLC purity, chromatographic traceability, and residual solvent data—structured for direct insertion into your method validation package. DMF-ready documentation, stability summaries, and custom quality agreements are available upon request.
Global reach with transparent pricing. Cosperpharm ships to pharmaceutical manufacturers, CROs, and analytical laboratories worldwide, with full customs documentation included.
Each batch undergoes HPLC purity verification, chiral purity assessment, identity confirmation via NMR and MS, and residual solvent analysis. Full batch traceability and COA documentation are provided.
Need Darolutamide intermediates for your manufacturing or analytical program? Contact Cosperpharm for pricing, documentation, or technical support.
